Market capitalization | $592.79m |
Enterprise Value | $631.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.49 |
P/S ratio (TTM) P/S ratio | 3.28 |
P/B ratio (TTM) P/B ratio | 5.96 |
Revenue growth (TTM) Revenue growth | 18.79% |
Revenue (TTM) Revenue | $180.86m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a AxoGen, Inc. forecast:
7 Analysts have issued a AxoGen, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 181 181 |
19%
19%
|
|
Gross Profit | 138 138 |
11%
11%
|
|
EBITDA | -0.72 -0.72 |
96%
96%
|
EBIT (Operating Income) EBIT | -8.50 -8.50 |
64%
64%
|
Net Profit | -14 -14 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Head office | United States |
CEO | Michael Dale |
Employees | 428 |
Founded | 1977 |
Website | www.axogeninc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.